Profusa 3Q 2026: EPS ($6.23) — 10-Q Summary
Profusa reported no revenue in Q3 2026, with net loss narrowing 81% YoY to $4.95M, and EPS at ($6.23). Expenses fell due to workforce reduction and lower costs. The company received ISO 13485:2016 certification for its Lumee Oxygen Platform.
How this was made

The 30-second read
Why it matters
The 10‑Q provides the first detailed expense breakdown and workforce reduction, offering insight into the company's path to profitability.
Market read
While the filing is material for PFSA shareholders, its scale limits broader market relevance.
What to watch
No revenue yet; reliance on future regulatory approvals and market adoption.
Background
Profusa is a micro‑cap med‑tech company developing oxygen‑delivery platforms, previously reporting larger losses.
Ticker impact
Profusa filed its 10‑Q reporting a net loss of $4.95 M and EPS of -$6.23, a material update that narrows loss 81% YoY.
modest downside pressure as investors weigh continued loss against expense reductions
Losses remain large; market may react negatively despite improvement, especially given low revenue.
Market effects
Highlights cost‑cutting trends in the med‑tech diagnostics space.
Limited to US micro‑cap investors.
Minimal broader market impact.
Counterpoint
The loss narrowing could signal a turnaround if expense discipline continues.
Key entities
- companyProfusa, Inc.
US‑listed med‑tech firm (ticker PFSA).